SCHEMBL3264614

SCHEMBL3264614

CN(C)CCc1cn(Cc2ccccc2Br)c2ccc(Br)cc12

nearest known ligand 0.54

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ HTR6 P50406 16/20 0.54
▸ TAAR1 Q96RJ0 1/20 0.52
▸ HDAC1 Q13547 1/20 0.46
▸ HDAC10 Q969S8 1/20 0.46
▸ HDAC8 Q9BY41 1/20 0.46
▸ HDAC6 Q9UBN7 1/20 0.46
▸ CYP19A1 P11511 1/20 0.42
▸ HTR1A P08908 1/20 0.41
▸ HTR1D P28221 1/20 0.41
▸ HTR1B P28222 1/20 0.41
▸ HTR1F P30939 1/20 0.41
▸ HTR7 P34969 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3250179 0.89 HTR6 (0.58) HTR6TAAR1HDAC1HDAC10HDAC8
SCHEMBL3252401 0.88 HTR6 (0.44) HTR6TAAR1CYP19A1
SCHEMBL3257594 0.88 HTR6 (0.60) HTR6TAAR1HDAC1HDAC10HDAC8
SCHEMBL3251339 0.88 HTR6 (0.52) HTR6TAAR1HDAC1HDAC10HDAC8
SCHEMBL3253620 0.87 HTR6 (0.69) HTR6TAAR1HDAC1HDAC10HDAC8
SCHEMBL3256699 0.87 HTR6 (0.43) HTR6TAAR1HDAC1HDAC10HDAC8
SCHEMBL1751353 0.86 HTR6 (0.72) HTR6TAAR1HDAC1HDAC10HDAC8
SCHEMBL3256595 0.86 HTR6 (0.74) HTR6HTR1AHTR1DHTR1BHTR1F
SCHEMBL6817354 0.81 HTR7 (0.48) HTR6TAAR1CYP19A1HTR1BHTR7
SCHEMBL28751628 0.79 HTR6 (0.42) HTR6CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1537113-B9 ARYLALKYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SUVEN LIFE SCIENCES LTD (IN) 2010-05-26 — — EP disclosed
EP-1537113-B1 ARYLALKYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SUVEN LIFE SCIENCES LTD (IN) 2009-10-07 — — EP disclosed
US-7297711-B2 Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them SUVEN LIFE SCIENCES LIMITED (IN) 2007-11-20 — — US disclosed
US-20050203103-A1 Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them SUVEN LIFE SCIENCES LIMITED (IN) 2005-09-15 — — US disclosed
EP-1537113-A1 ARYLALKYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Suven Pharmaceuticals Ltd. (IN) 2005-06-08 — — EP disclosed
WO-2004000845-A1 ARYLALKYL INDOLES HAVING SERTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SUVEN LIFE SCIENCES LIMITED (IN) 2003-12-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203103-A1 Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them TPH1, HTR1A, HTR7 HTR6 9/4885TAAR1 39/4885HDAC1 3609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback